Viking Historical Cash Flow
| VKTX Stock | USD 33.40 0.03 0.09% |
Analysis of Viking Therapeutics cash flow over time is an excellent tool to project Viking Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 20.2 M or Other Cashflows From Financing Activities of 327.7 M as it is a great indicator of Viking Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Viking Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Viking Therapeutics is a good buy for the upcoming year.
Viking |
About Viking Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Viking balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Viking's non-liquid assets can be easily converted into cash.
Viking Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Viking Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Viking Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.At this time, Viking Therapeutics' Change To Account Receivables is fairly stable compared to the past year. Other Cashflows From Investing Activities is likely to rise to about 66.1 K in 2025, despite the fact that Free Cash Flow is likely to grow to (62.7 M).
Viking Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Viking Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Viking Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Stock Based Compensation | 5.8M | 6.1M | 8.7M | 16.8M | 19.3M | 20.2M | |
| Free Cash Flow | (21.8M) | (47.6M) | (48.4M) | (73.4M) | (66.0M) | (62.7M) | |
| Other Cashflows From Financing Activities | 950K | 6.9M | 11.0M | 271.4M | 312.1M | 327.7M | |
| Other Non Cash Items | 138K | 29K | 1.3M | (8.1M) | (7.3M) | (6.9M) | |
| Total Cash From Operating Activities | (21.8M) | (47.6M) | (48.4M) | (73.4M) | (66.0M) | (62.7M) | |
| Net Income | (39.5M) | (55.0M) | (68.9M) | (85.9M) | (77.3M) | (73.4M) | |
| Total Cash From Financing Activities | 950K | 6.9M | 4.2M | 271.4M | 312.1M | 327.7M | |
| Sale Purchase Of Stock | (296.0) | (707.0) | (6.8M) | (7.1M) | (6.4M) | (6.1M) | |
| Change In Cash | 20.7M | (2.7M) | 10.3M | 18.9M | 21.7M | 22.8M | |
| Change In Working Capital | 7.7M | (2.9M) | 10.2M | 3.5M | 3.2M | 3.0M | |
| End Period Cash Flow | 29.1M | 26.4M | 36.6M | 55.5M | 63.8M | 67.0M | |
| Change To Liabilities | 3.9M | 5.3M | (3.1M) | 12.9M | 11.6M | 12.2M | |
| Investments | 41.6M | 38.0M | 54.8M | (207.6M) | (186.8M) | (177.5M) | |
| Begin Period Cash Flow | 8.4M | 29.1M | 26.4M | 36.6M | 42.1M | 44.2M | |
| Total Cashflows From Investing Activities | 7.5M | 41.6M | 38.0M | 54.8M | 63.0M | 66.1M | |
| Depreciation | 277K | 296K | 291K | 292K | 262.8K | 249.7K | |
| Change To Operating Activities | (5.3M) | 6.2M | (383K) | 3.1M | 2.8M | 2.6M | |
| Change To Netincome | 3.7M | 5.8M | 6.1M | 8.7M | 10.0M | 10.5M | |
| Cash And Cash Equivalents Changes | (16.4M) | 20.7M | (2.7M) | 10.5M | 12.1M | 12.7M | |
| Cash Flows Other Operating | (7.1M) | 2.8M | 448K | (2.3M) | (2.1M) | (2.0M) | |
| Other Cashflows From Investing Activities | 7.5M | 41.6K | 38.0K | 54.8K | 63.0K | 66.1K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.